A new United States Medicare drug pricing model could apply to just four manufacturers after sweeping exemptions for companies with separate White House agreements. The policy shift slashes projected government savings by more than 96%. The narrowing scope limits the program's immediate impact on hospital drug expenditures.

GLOBE Model Narrows